Skip to main content

PD-L1 IHC 28-8 pharmDx for melanoma

The first and only CE-IVD marked PD-L1 test for use in the assessment of patients for whom OPDIVO® (nivolumab) and YERVOY® (ipilimumab) combination treatment is being considered in melanoma.1

Demonstrated clinical results1, 2

PD-L1 IHC 28-8 pharmDx demonstrated clinical results in the phase 3 CheckMate-067 clinical trial.

The CheckMate -067 study was a three armed study of OPDIVO® (nivolumab) monotherapy or OPDIVO in combination with YERVOY® (ipilimumab) versus YERVOY monotherapy

Progression free survival was evaluated across PD-L1 subgroups.

PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in melanoma may be used as an aid in the assessment of patients for whom OPDIVO (nivolumab) and YERVOY (ipilimumab) combination treatment is being considered.

Robust performance

PD-L1 IHC 28-8 pharmDx is CE-IVD marked and fully validated with analytical performance having met all pre-determined acceptance criteria for sensitivity, specificity, repeatability, and reproducibility.1

Selected analytical validation parameters Results for metastatic melanoma
Analytical Specificity
  • Primary antibody: rabbit monoclonal, clone 28-8
  • Detects PD-L1 on the plasma membranes of tumor cells, the staining of which can be completely abolished by PD-L1 gene knock-out 3
  • Detection in normal tissues is restricted to immune cells and infrequently the cells of epithelial origin
  • Clone 28-8 exhibits no cross reactivity to PD-L2
Sensitivity
  • Broad dynamic range of PD-L1 expression (0-100% tumor cells positive, 0-3 staining intensity) exhibited in study of 104 unique cases of melanoma archival FFPE specimens
  • In BMS clinical study CheckMate CA209067 of patients with melanoma, approximately 58% had PD-L1 expression levels ≥1% and approximately 28% had PD-L1 expression levels ≥5%
Repeatability
  • Repeatability testing of inter-instrument, inter-operator, inter-day, inter-lot and intra-run performance
  • ≥ 90% overall agreement for ≥1% expression level
  • 95% confidence intervals ranged from 83.2 to 99.4% in ≥1% and 77,6 to 96,4 in ≥5% for ANA, APA, and OA*
External Reproducibility
  • Reproducibility testing day-to-day, site-to-site and observer-to-observer performance in a blinded study in three certified clinical labs
  • ≥ 90% overall agreement for ≥1% expression level
  • 95% confidence intervals ranged from 88.1 to 100% for ANA, APA, and OA*

*Average Negative Agreement, Average Positive Agreement, and Overall Agreement

Order Information
Product Code
PD-L1 IHC 28-8 pharmDx SK005

Required but not included in kit:

EnVision FLEX Wash Buffer, 20x

EnVision FLEX Hematoxylin (Link)

PT Link


AS480

K8007

K8008

PT101

References

1. PD-L1 IHC 28-8 pharmDx Instruction For Use

2. Clinical Trial: Checkmate 067, CA209067

3. Phillips T, Simmons P, Inzunza H, Cogswell J, Novotny J, Taylor C, Zhang X.
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non.small cell lung cancer. Appl Immunohistochem Mol Morph 2015;8:541-9

Want to hear more about PD-L1 IHC 28-8 pharmDx?

Contact your local sales representative

Product Information

Product details, specification sheet and safety data sheet (SDS).

Intended Use

For in vitro diagnostic use

PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC) and melanoma tissue using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of tumor cells exhibiting positive membrane staining at any intensity.

PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC may be associated with enhanced survival from OPDIVO® (nivolumab).

PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in melanoma may be used as an aid in the assessment of patients for whom OPDIVO® (nivolumab) and YERVOY® (ipilimumab) combination treatment is being considered.1